LBRX · Lb Pharmaceuticals Inc

$47.71 +0.48 (+1.02%)

Market Cap

$1.54B

32.26M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Heather Turner	Chief Executive Officer	$568,750	$321,406	—	$10,865,221	—	$129,608	$11,884,985
Anna Eramo	Chief Medical Officer	$414,063	$182,188	—	$1,760,006	—	$20,682	$2,376,939

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Heather Turner	Chief Executive Officer	$68,750	—	—	$4,709,607	—	$14,333	$4,792,690
Anna Eramo	Chief Medical Officer	$375,000	$262,500	—	$239,750	—	$13,800	$891,050

Executive changes

Person	Role	Change	Effective	Filed
Anna Eramo, M.D.	Chief Medical Officer	Resigned	2026-06-15	2026-06-10
Zachary Prensky	member of the Board	Retired	—	2026-03-16
Gad Soffer	Chief Operating and Business Officer	Appointed	2026-03-04	2026-03-10
Robert A. Lenz	Class I director	Appointed	2026-03-06	2026-03-10

Key facts CIK 1691082 CUSIP 50180M108 13F (30d) 113 filings 112 filers Visit website Investor relations